Mithra Pharmaceuticals S.A. (MITPF)
Mithra Pharmaceuticals S.A. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Liège, BE. The stock last traded at $23.90, up 254.07% on the session, giving a market capitalisation of $1.60B. On trailing twelve-month figures it carries a trailing P/E of -0.09, a net margin of -432.1%. Its beta of 0.60 implies it has historically moved less than the broad market.
Mithra Pharmaceuticals S.A., established in 1999 and headquartered in Liège, Belgium, is a pharmaceutical company dedicated to the global development, manufacturing, and marketing of advanced therapeutic solutions. The firm's primary focus areas include women's health, specifically addressing contraception, menopause management, and hormone-dependent cancers. Its robust product pipeline features Estelle, a combined oral contraceptive that has successfully completed Phase III clinical trials, and Donesta, an estetrol-based oral hormone treatment currently undergoing Phase III development. Mithra's portfolio also includes Myring, a hormone-releasing contraceptive vaginal ring; Tibelía, designed to treat menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant utilized for prostate and breast cancers, alongside various benign gynecological indications. Additionally, the company offers NEXTSTELLIS, an oral contraceptive pill. Beyond specific drug formulations, Mithra's manufacturing capabilities extend to diverse pharmaceutical forms, such as polymeric products, implants, sterile injectable products, and hormonal tablets.
Mithra Pharmaceuticals S.A. is most often compared with the following Healthcare names: